MedTrace Logo

Efficacy of Mepolizumab in Polish Patients With Severe Eosinophilic Asthma

NCT05091385 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 106

Last updated 2026-01-28

Study results available
· View outcomes & findings →

Summary

This study is aimed at evaluation of the efficacy of mepolizumab 100 mg subcutaneously (SC) every 4 weeks in patients with severe eosinophilic asthma who have been treated for at least 12 months in several Polish allergy/asthma centres under the same protocol. Target population to be recruited has been set at 130 subjects from at least 6 asthma centers throughout the country. Data on demographics and asthma status will be collected using questionnaires at 3 time-points: pre-mepolizumab (pre-MEPO), after 24 weeks of mepolizumab (MEPO) and after 1 year of MEPO administration (some of the outcomes will be observed every 4 weeks). Primary endpoints will include:

* Asthma exacerbations measured at qualification for the treatment (in the period of previous 52 weeks) and at the 24th and 52nd week of the treatment.
* Oral Corticosteroids use dose (documented at qualification for the treatment and at the 24th and 52nd week of the treatment).

Conditions

  • Asthma; Eosinophilic

Interventions

BIOLOGICAL

Mepolizumab given SC 100mg every 4 weeks between Dec 2017 and Dec 2019

Mepolizumab administered within the frame of a severe asthma treatment program financed by National Health Fund in Poland for patients fulfilling specific criteria of asthma severity.

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Medical University of Lodz

    lead OTHER

Principal Investigators

  • Marcin Kurowski, MD, PhD · Medical University of Lodz

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2024-06-30
Completion
2025-08-06
FDA Drug
Yes

Countries

  • Poland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05091385 on ClinicalTrials.gov